
Loxoprofen sodium
CAS No. 80382-23-6
Loxoprofen sodium ( —— )
产品货号. M32733 CAS No. 80382-23-6
Loxoprofen sodium 是一种具有口服活性和解热作用的非甾体类抗炎药,可用于缓解疼痛的研究。Loxoprofen sodium 是一种非选择性 COX 抑制剂,对 COX-1 和 COX-2 的 IC50 分别为 6.5 和 13.5 μM。Loxoprofen sodium 可降低动脉粥样硬化,并具有抗肿瘤活性。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
10MG | ¥315 | 有现货 |
![]() ![]() |
25MG | ¥485 | 有现货 |
![]() ![]() |
50MG | ¥712 | 有现货 |
![]() ![]() |
100MG | ¥1017 | 有现货 |
![]() ![]() |
500MG | ¥2547 | 有现货 |
![]() ![]() |
1G | ¥3810 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Loxoprofen sodium
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Loxoprofen sodium 是一种具有口服活性和解热作用的非甾体类抗炎药,可用于缓解疼痛的研究。Loxoprofen sodium 是一种非选择性 COX 抑制剂,对 COX-1 和 COX-2 的 IC50 分别为 6.5 和 13.5 μM。Loxoprofen sodium 可降低动脉粥样硬化,并具有抗肿瘤活性。
-
产品描述Loxoprofen sodium is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen sodium is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen sodium can reduce atherosclerosis and shows antitumor activity.
-
体外实验Loxoprofen sodium, an anti-inflammatory prodrug (NSAID), is a nonselective COX inhibitor with IC50s of 6.5 and 13.5μM for COX-1 and COX-2 in human whole blood assays, respectively.Loxoprofen (LOX) sodium is a non-selective cyclooxygenase inhibitor that is widely used for the reasearch of pain and inflammation caused by chronic and transitory conditions. Its alcoholic metabolites are formed by carbonyl reductase (CR) and they consist of trans-LOX, which is active, and cis-LOX, which is inactive. In addition, LOX sodium can also be converted into an inactive hydroxylated metabolite (OH-LOXs) by cytochrome P450 (CYP).
-
体内实验Loxoprofen sodium (4 mg/kg/day; p.o.; 1 or 8 weeks) reduces atherosclerosis in mice by reducing inflammation.Loxoprofen sodium (60 μg/mL; p.o.; 24 days) suppresses mouse tumor growth by inhibiting VEGF.Animal Model:ApoE-/- mice (C57BL/6J-Apoetm1Unc) with high-fat diet (0.2% cholesterol, 21% saturated fat) from 8 to 16 weeks of ageDosage:4 mg/kg/day in drinking water Administration:Oral dosing from 8 to 16 weeks of age or from 15 to 16 weeks of age Result:Inhibited platelet thromboxane production and platelet aggregation. Reduced extent of atherosclerosis. Suppressed the production of PGE2, TxB2 and PGI2.Animal Model:6-week-old male C57BL/6 and BDF1 mice, 100 μL suspensions (2 × 106 cells/mL) of LLC cells and KLN205 cells were injected subcutaneously into C57BL/6 and BDF1 mice, respectively.Dosage:60 μg/mL Administration:Oral dosing in drinking water, every day for 24 daysResult:Suppressed tumor growth and angiogenesis, suppressed expression of VEGF in mice with LLC tumor, inhibited tubular formation of HUVECs.
-
同义词——
-
通路Chromatin/Epigenetic
-
靶点COX
-
受体COX
-
研究领域——
-
适应症——
化学信息
-
CAS Number80382-23-6
-
分子量268.2834
-
分子式C15H17NaO3
-
纯度>98% (HPLC)
-
溶解度In Vitro:?H2O 中的溶解度 : 100 mg/mL (372.74 mM; 超声助溶) DMSO 中的溶解度 : 19.23 mg/mL (71.68 mM; 超声助溶 )。
-
SMILES[Na+].CC(C([O-])=O)C1=CC=C(CC2CCCC2=O)C=C1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Riendeau D, et al. Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2. Bioorg Med Chem Lett. 2004;14(5):1201-1203.?